Interim Report 2026

For the Six Months Ended 30 June 2026





Doctor Care Anywhere Group plc
(Company Number 08915336)
(ARBN 645 163 873)

Appendix 4D: Half Year Report

For the Six Months Ended 30 June 2026

(previous corresponding period six months ended 30 June 2025)

Doctor Care Anywhere Group plc

Company number: 08915336

ARBN: 645 163 873

This report comprises the half year information given to ASX under Listing Rule 4.2A.

This information should be read in conjunction with the most recent annual financial report of Doctor Care Anywhere Group plc for the year ended 31 December 2025.

Date: 17 August 2026

Contents

Appendix 4D – Half Year Report

Current reporting period ("H1 26"): 1 January 2026 to 30 June 2026

Previous corresponding period ("H1 25"): 1 January 2025 to 30 June 2025

The Appendix 4D and Half year Financial Report presents the results of Doctor Care Anywhere Group plc ("the Company", DCA" or "Doctor Care Anywhere") and the entities it controlled (collectively "the Group") at the end of or during the period ended 30 June 2026.

This information should be read in conjunction with the Doctor Care Anywhere Group plc 2025 Annual Report.

Basis of Preparation

This Appendix 4D has been prepared in accordance with measurement and recognition requirements of UK-Adopted IAS 34.

The interim results for the 6 months ended 30 June 2026 and the comparatives for 30 June 2025 are unaudited but have been reviewed by the Company's independent auditor. A copy of the review report is included at the end of this report. Note all values in the Appendix 4D and Directors' Report are subject to rounding differences.

Results for Announcement to the Market

DCA is pleased to report continued profit and positive cash generation during H1 26.

The business is now sustainably cash generative having continued to build upon the transformative work executed during the previous financial year. The focused effort to transform our operating model, streamline operations and deliver a more efficient service now has sustainable traction.

In addition to the continuation of operational efficiencies and cost control, the Board was extremely pleased to have completed the acquisition of the trade and assets associated with a weight management business. The incorporation of DCA Medicspot Ltd, established in May 2026, positions DCA firmly in one of the fastest-growing areas of private healthcare in the country, GLP-1 weight-loss treatment and ongoing weight management support.

Strategically, DCA Medicspot provides an immediate presence in the UK weight-management market and adds a complementary service in strong demand, alongside significant cross-selling opportunities across DCA's existing virtual GP, mental health, physiotherapy and health assessment customer base, accelerating the Company's wider direct-to-consumer strategy.

The Executive team are looking forward to delivering the results to the market via roadshows in Australia during the final quarter of the financial year.

		H1 26	H1 25	Change	%
Revenue from ordinary activities	£m	20.4	19.2	1.2	*6.3%*
EBITDA	£m	2.6	2.1	0.6	*27.1%*
Profit from ordinary activities after tax attributable to members	£m	0.6	0.5	0.1	*28.3%*
Net profit attributable to members	£m	0.6	0.5	0.1	*28.3%*
Cash	£m	7.7	4.8	2.9	*60.3%*
Net tangible liability per security	p	1.6	1.8	0.3	*15.1%*

Dividends

No interim dividend has been declared or paid in respect of the period (H1 25: nil). Record date for determining entitlements to a dividend: not applicable. The Company does not operate a dividend reinvestment plan.

Control gained or lost over entities during the period

DCA Medicspot Ltd was incorporated in May 2026 as a wholly owned subsidiary of the Company and control was obtained on incorporation. No entities ceased to be controlled during the period.

Associates and joint ventures

The Group holds an investment in My Emergency Doctor Limited carried at £140,000 (31 December 2025: £140,000). The Group does not account for any entity as an associate or joint venture.

Explanation of the above information

Please refer to the Directors' Report for a review of the Group's operations and financial performance for the six months ended 30 June 2026.

This report was authorised for release to ASX by the Board of Directors of Doctor Care Anywhere Group plc.

Investor Queries
Matthew Pearson – Investor Relations
Doctor Care Anywhere Group plc
investorenquiries@doctorcareanywhere.com

Directors' Report

The Directors present the condensed consolidated interim financial report of Doctor Care Anywhere Group plc ("the Company", DCA" or "Doctor Care Anywhere") and the entities it controlled (collectively "the Group") for the six months ended 30 June 2026 ("H1 26").

Directors

The Directors in office during the reporting period and as at the date of this report are shown below:

- John Stier — Independent Non-Executive Chairman
- David Ravech — Non-Executive Director
- Matthew Addison — Non-Executive Director
- Samit Shah — Independent Non-Executive Director
- Laura O'Riordan — Chief Executive Officer

About Doctor Care Anywhere

Doctor Care Anywhere Group plc is one of the UK's largest private providers of telehealth services. The Company works with insurers, healthcare providers and corporate customers to connect patients to a range of digitally enabled telehealth services on its proprietary platform.

Principal Activities

The principal activities of the Group during the period were the provision of digitally enabled primary care and telehealth services in the United Kingdom, including virtual GP consultations, mental health, physiotherapy and health assessments, and from May 2026 weight management services. There was no significant change in the nature of those activities during the period other than the addition of weight management services.

Operating Review

During the first half of FY26, DCA continued to strengthen its position as a leading digital healthcare provider, with a focus on improving patient engagement, expanding service offerings and investing in future growth.

000's	H1 26	H1 25	Change	%
Consultations	354.9	349.9	5.0	*1.4%*
Repeat Patients	262.7	255.1	7.6	*3.0%*
First-Time Patients	92.2	94.8	(2.6)	*(2.8%)*

Consultation volumes were 354,900 in H1 FY26, up 1.4% on the pcp. Growth in consultations was driven by enhancements to the booking journey, which improved the patient experience and increased conversion from member to user. These improvements reduced friction in the booking process, making it easier for patients to access care and contributing to higher levels of engagement across the platform. This has also resulted in increased levels of repeat patients.

Repeat patients represented 74.0% of consultations in H1 26, consistent with the second half of FY25 and up from 72.9% in H1 25. Approximately three quarters of all consultations are now delivered to returning patients, reflecting the Company's focus on engagement and continuity of care.

Acquisition of the weight management business

On 8 May 2026 the Group entered into a binding asset purchase of the GLP-1 and medicated weight loss business of Outcome Diagnostics Limited and Medic Spot Limited. The trade and assets were acquired for consideration of £0.9 million through the Group's newly incorporated subsidiary, DCA Medicspot Ltd.

The acquisition broadens the Group's revenue base and adds a direct to consumer channel alongside the Group's existing insurer and corporate relationships, with cross selling opportunities across its virtual GP, mental health, physiotherapy and health assessment customer base. DCA Medicspot contributed revenue of £0.9 million during the period to 30 June 2026 and was approximately breakeven at an operating level. The Group expects to integrate the acquired services across its sales channels during the second half.

Ramsay Health Care UK partnership

During the period the Group agreed a new partnership with Ramsay Health Care UK. The collaboration gives Ramsay patients access to self-pay online GP appointments, with onward referral into Ramsay's network of hospitals and specialists where secondary care is required - creating a joined-up, end-to-end care journey. Patients will be referred seamlessly from DCA primary care services straight into a secondary care pathway with Ramsay Health Care UK. This new partnership delivers the progress DCA is seeking in setting new standards for integrated virtual and in-person care and enabling earlier, effective intervention.

Investment

The Group continued to invest in business development, marketing and technology capabilities during the period, supporting customer acquisition, consultation volumes and platform functionality.

Financial Review

Consolidated income statement

£m's	H1 26	H1 25 restated*	Change	%
Revenue	**20.4**	**19.2**	**1.2**	***6.3%***
Operating costs	(11.9)	(11.3)	(0.5)	*(4.6%)*
Contribution	**8.6**	**7.9**	**0.7**	***8.8%***
Contribution Margin	*42.0%*	*41.0%*	*0.9 ppt*	
Non-operating costs	(6.0)	(5.8)	(0.1)	*(2.3%)*
EBITDA	**2.6**	**2.1**	**0.6**	***27.1%***
EBITDA Margin	*12.8%*	*10.7%*	*2.1 ppt*	
Depreciation and amortisation	(1.6)	(1.2)	(0.4)	*(33.4%)*
EBIT	**1.1**	**0.9**	**0.2**	***18.6%***
Finance income and expense	(0.4)	(0.4)	(0.1)	*(21.4%)*
Profit before tax	**0.6**	**0.5**	**0.1**	***16.7%***
Tax	(0.0)	(0.0)	0.0	*100.0%*
Profit after tax	**0.6**	**0.5**	**0.1**	***28.5%***
Net operating cash flows	**3.8**	**1.9**	**1.9**	***99.8%***

*In line with the annual report certain costs previously reported as non-operating expenses have been reclassified to operating expenses to more accurately reflect the activities of the business. The directors regard contribution as a key performance indicator, and this reclassification ensures it is presented on a more consistent basis. Contribution now has the same definition as gross profit in the financial statements which has been revised since the H1 25 results presentation.

Revenue

Revenue increased by 6.3% in H1 26 compared with H1 25. Of the £1.2m increase, £0.9m was contributed by DCA Medicspot Ltd. Revenue in the existing business grew 1.7%, in line with consultation growth of 1.4%. Subscription revenue increased from 7.1% of total revenue to 10.8%, reflecting the acquisition and the continued shift towards direct-to-consumer channels.

Contribution

Contribution in H1 26 was £8.6m, up 8.8% on H1 25. Contribution margin of 42.0% was 0.9 percentage points higher than H1 25, driven by revenue growth, increased marketing investment, improvements to the booking journey and continued growth in direct-to-consumer channels.

EBITDA

EBITDA profit in H1 26 has increased to £2.6m, an increase of 27.1% on H1 25. This EBITDA improvement is driven by the operating model changes that have increased contribution along with a reduction in underlying fixed costs. Administrative costs fell following the prior period restructure, partially offset by investment in business development, marketing and technical resource.

Net profit

Net profit for the period was £0.6m, up 28.5% on H1 25, reflecting revenue growth, improved operating performance and continued cost control across the Group.

Cash

Cash and cash equivalents at 30 June 2026 were £7.7m, up 60.3% on 30 June 2025. After capital expenditure and investment in the platform, the Group generated free cash flow of £1.5m in H1 26 compared with £0.7m in H1 25, while funding the £0.9m acquisition of the weight management business from existing resources.

The £10.6m convertible loan note remains in place, with no principal repayment required until 31 December 2027.

In July 2026 ASX granted the Company relief from the quarterly reporting requirements of Listing Rules 4.7B and 4.7C.

Net tangible liability per security

Net tangible liabilities decreased by £1.1 million from £6.8 million at 30 June 2025 to £5.7 million at 30 June 2026.

As a result of the above, net tangible liabilities per security decreased from 1.8p at 30 June 2025 to 1.6p at 30 June 2026.

This report is made in accordance with a resolution of the directors of the company.

John Stier

John Stier, Chair:

Date: 17 August 2026

Unaudited Interim Condensed Consolidated Financial Statements

Prepared under International Accounting Standard 34 for the six-month period ended 30 June 2026

Interim Condensed Consolidated Statement of Comprehensive Income

	Note	**30 June 2026 Unaudited £'000**	*30 June 2025 Unaudited (restated*) £'000*
Revenue	3	**20,437**	*19,225*
Cost of sales		**(11,860)**	*(11,338)*
Gross profit		**8,577**	*7,887*
Administrative expenses	4	**(7,527)**	*(7,138)*
Other operating income	5	**-**	*136*
Operating profit	6	**1,050**	*885*
Finance income		**22**	*4*
Finance costs	7	**(467)**	*(370)*
Profit before taxation		**605**	*519*
Tax charge	8	**-**	*(48)*
Total comprehensive income for the period		**605**	*471*
Profit per share		**P**	P
Basic EPS	9	**0.2**	0.1
Diluted EPS	9	**0.2**	0.1

*At the financial year-end, management reviewed the classification of cost of sales and determined that several direct operating costs should be included to provide a more accurate presentation of cost of sales. This classification has been applied in H1 26, and the comparative H1 25 period has been reassessed and restated accordingly. These adjustments are solely presentational in nature and do not affect the reported results for either period.

The notes on pages 13 to 23 form part of these interim condensed consolidated financial statements.

Interim Condensed Consolidated Statement of Financial Position

	Note	30 June 2026 Unaudited £'000	31 December 2025 Audited £'000
Non-current assets			
Property, plant and equipment	10	**608**	*747*
Intangible assets	11	**7,583**	*6,751*
Investments	12	**140**	*140*
Total non-current assets		**8,331**	*7,638*
Current assets			
Trade and other receivables	13	**3,148**	*2,996*
Cash and cash equivalents		**7,676**	*6,575*
Total current assets		**10,824**	*9,571*
Current liabilities			
Trade and other payables	14	**(6,854)**	*(5,745)*
Loans and borrowings		**(139)**	*(417)*
Total current liabilities		**(6,993)**	*(6,162)*
Non-current liabilities			
Trade and other payables	15	**(1,104)**	*(1,238)*
Loans and borrowings	16	**(9,220)**	*(8,790)*
Total non-current liabilities		**(10,324)**	*(10,028)*
Net assets		**1,838**	*1,019*
Capital and reserves			
Called up share capital		**78**	*78*
Share premium account		**56,229**	*56,212*
Other reserves		**4,105**	*5,994*
Retained losses		**(58,574)**	*(61,265)*
Total equity		**1,838**	*1,019*

The notes on pages 13 to 23 form part of these interim condensed consolidated financial statements. The interim condensed consolidated financial statements were approved and authorised for issue by the Board and were signed on its behalf by:

John Stier

John Stier, Chair:

Date: 17 August 2026

Interim Condensed Consolidated Statement of Changes in Equity

For the six months ended 30 June 2026

	Called up share capital Unaudited £'000	Share premium account Unaudited £'000	Other reserves Unaudited £'000	Retained losses Unaudited £'000	Total equity Unaudited £'000
At 1 January 2026	**78**	**56,212**	**5,994**	**(61,265)**	**1,019**
Comprehensive income for the period	-	-	-	605	**605**
Total comprehensive income for the period	-	-	-	605	**605**
Share based payments	-	-	214	-	**214**
Issue of shares on exercise of share options	-	17	(17)	-	-
Transfer of lapsed share options to retained earnings	-	-	(2,086)	2,086	-
At 30 June 2026	**78**	**56,229**	**4,105**	**(58,574)**	**1,838**

Interim Condensed Consolidated Statement of Changes in Equity

For the six months ended 30 June 2025

	Called up share capital Unaudited £'000	Share premium account Unaudited £'000	Other reserves Unaudited £'000	Retained losses Unaudited £'000	Total equity Unaudited £'000
At 1 January 2025	**78**	**56,212**	**5,485**	**(62,420)**	**(645)**
Comprehensive income for the period	-	-	-	471	**471**
Total comprehensive income for the period	-	-	-	471	**471**
Share based payments	-	**-**	102	-	**102**
Foreign exchange movements	-	**-**	(17)	-	**(17)**
At 30 June 2025	**78**	**56,212**	**5,570**	**(61,949)**	**(89)**

The notes on pages 13 to 23 form part of these interim condensed consolidated financial statements.

Interim Condensed Consolidated Statement of Cash Flows

	Period ended 30 June 2026 Unaudited £'000	*Period ended 30 June 2025 Unaudited £'000*
Cash flows from Operating Activities		
Receipts from customers	**20,778**	*19,237*
Payments to suppliers and employees	**(17,035)**	*(17,699)*
Finance income received	**22**	*4*
Government grants and tax incentives	**-**	*342*
Total Cash flows from Operating Activities	**3,765**	*1,884*
Cash flows from Investing Activities		
Payment for property, plant and equipment	**(15)**	*(10)*
Purchase of intangible fixed assets	**(2,261)**	*(1,169)*
Total Cash flows from Investing Activities	**(2,276)**	*(1,179)*
Cash flows from Financing Activities		
Repayment of borrowings	**(278)**	*-*
Payment of lease liabilities	**(110)**	*(321)*
Total Cash flows from Financing Activities	**(388)**	*(321)*
Net Cash flows	**1,101**	*384*
Cash and cash equivalents at beginning of period	**6,575**	*4,407*
Effect of movement in exchange rates on cash held	**-**	*(2)*
Cash and cash equivalents at the end of period	**7,676**	*4,789*
Included in cash and cash equivalents per the balance sheet	7,676	4,789

The notes on pages 13 to 23 form part of these interim condensed consolidated financial statements.

Notes to the Interim Condensed Financial Statements

For the six-month period ended 30 June 2026

1. Corporate information

Doctor Care Anywhere Group plc ('the Company') and its subsidiary undertakings (together referred to as the 'Group') are engaged in digital healthcare service and development.

Doctor Care Anywhere Group plc is a public company limited by shares and registered in England and Wales, registered number 08915336. Its registered office is located at 19-21 Great Portland Street, London, England, W1W 8QB. It is listed on the Australian Securities Exchange (ASX:DOC).

These interim condensed consolidated financial statements are unaudited and do not constitute the statutory accounts within the meaning of Section 434 of the Companies Act 2006. The Group's most recent statutory financial statements, which comprise the Annual Report and audited Financial Statements for the year ended 31 December 2025 were approved by the Board of Directors on 28 March 2026 and delivered to the Registrar of Companies. The report of the auditor on those financial statements was not qualified, did not contain an emphasis of matter paragraph and did not contain any statement under Section 498 of the Companies Act 2006.

2. Material accounting policies

2.1. Basis of preparation

The unaudited interim condensed consolidated financial statements cover Doctor Care Anywhere Group plc and the entities it controlled at the end of, or during, the half year ended 30 June 2026, and have been prepared in accordance with IAS 34, Interim Financial Reporting. The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements and should be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 December 2025 prepared in accordance with UK-adopted international accounting standards.

2.2. Going concern

These financial statements have been prepared on a going concern basis, which assumes that the Group will continue to be able to meet its liabilities as they fall due for the foreseeable future, which is defined as a period of not less than twelve months from the signing of these accounts.

The Company has prepared a cash flow forecast through to August 2027 on a going concern basis, and the directors have considered this forecast and a range of sensitivities carefully. The Directors are of the view that there is a reasonable expectation that the Group has adequate resources to continue in operational existence for that period, and they have not identified any material uncertainties that may cast significant doubt on the Group's ability to continue as a going concern. The Company therefore adopts the going concern basis of accounting in preparing these consolidated financial statements.

2.3. Critical accounting judgements and key sources of estimation uncertainty

The preparation of the interim condensed financial statements requires management to make estimates, judgements and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses. These estimates, judgements and assumptions are based on historical experience and other factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates. The critical accounting judgements and the major sources of estimation uncertainty were largely the same as those described in the previous annual financial statements for the year ended 31 December 2025. Details of the estimates and judgements are included on page 68 of the 2025 Annual Report. New estimates and judgements in the six-month period are set out below:

Classification of Acquisition of Trade and Assets of a Weight Management Business

In May 2026, the Group acquired the trade and assets associated with a weight management business through its newly incorporated subsidiary, DCA Medicspot Ltd.

Management assessed whether the transaction should be accounted for as a business combination under IFRS 3 Business Combinations or as an asset acquisition. In making this assessment, management applied the optional concentration test available under IFRS 3 and concluded that substantially all of the fair value of the gross assets acquired was concentrated in a single identifiable intangible asset, being the acquired platform.

Accordingly, the transaction was determined to be an asset acquisition rather than a business combination. The consideration paid, together with directly attributable acquisition costs, has been capitalised as an intangible asset. The acquired platform is being amortised over its estimated useful economic life of three years, consistent with the Group's accounting policy for platform-related intangible assets.

3. Revenue

	Period ended 30 June 2026 Unaudited £'000	*Period ended 30 June 2025 Unaudited £'000*
Utilisation	**18,227**	*17,864*
Subscription	**2,210**	*1,349*
Other	**-**	*12*
Total revenue	**20,437**	*19,225*

Revenue streams are analysed between Utilisation, Subscription and Other services as follows:

Utilisation revenue

United Kingdom: Individually purchased consultations: revenue is recognised at a point in time, when the one distinct performance obligation, the consultation, is complete.

Subscription revenue

Monthly or Annual service subscription: there is one distinct performance obligation, being the provision of healthcare products and services. Revenue is recognised in the accounting period in which the products and services are rendered. The contracts are satisfied monthly over the contract term. Revenue is recognised over time, on a systematic basis over the period of the contract, as this represents the pattern of delivery of the performance obligation to customers.

A **contract asset** is recognised for revenue where the performance obligation (being the provision of utilisation and subscription services) has been completed, but payment remains conditional on acceptance by the customer. Once invoiced, the amount recognised as contract assets is reclassified to trade receivables.

A **contract liability** is recognised if a payment is received or a payment is due (whichever is earlier) from a customer before the Group transfers the related goods or services or for instances where the customer is invoiced in advance. Contract liabilities are recognised as revenue when the Group performs under the contract (i.e., transfers control of the related goods or services to the customer). Contract liabilities arise from annual service subscriptions and technology platform licensing.

4. Administrative expenses

	Period ended 30 June 2026 Unaudited £'000	*Period ended 30 June 2025 Unaudited (restated) £'000*
Technology costs	**1,428**	*2,135*
Sales and Marketing costs	**631**	*252*
General and Administration costs	**5,468**	*4,751*
	7,527	*7,138*

Technology costs include the expenses attributable to the development and maintenance of the Group's intellectual property which do not meet the capitalisation criteria under IAS 38.

Sales and Marketing costs include the expenses attributable to the selling and marketing of the Group's services.

General and Administration costs include the expenses attributable to supporting the Group's operating functions, depreciation, amortisation, and share-based payments.

5. Other Operating Income

Other operating income reported in the Interim Condensed Consolidated Statement of Comprehensive Income consists of the following:

	Period ended 30 June 2026 Unaudited £'000	*Period ended 30 June 2025 Unaudited £'000*
Rental Income	**-**	*136*
	-	*136*

6. Operating profit

The operating profit is stated after charging/(crediting):

	Period ended 30 June 2026 Unaudited £'000	Period ended 30 June 2025 *Unaudited (restated) £'000*
Cost of sales employee costs	**6,922**	*8,026*
Cost of sales contractor costs	**2,566**	*1,860*
Administrative expenses employee costs	**3,729**	*4,178*
Administrative expenses contractor costs	**1,229**	*1,126*
Depreciation	**138**	*147*
Amortisation of intangible assets	**1,429**	*1,027*
Exchange (gain)/loss	**7**	*(22)*

Employee costs consist of:

	Period ended 30 June 2026 Unaudited £'000	Period ended 30 June 2025 *Unaudited (restated) £'000*
Wages and salaries	**9,088**	*10,773*
Social security costs	**1,168**	*1,159*
Costs of defined contribution scheme	**181**	*170*
Share-based payment	**214**	*102*
	10,651	*12,204*

7. Finance costs

Finance costs consist of the following:

	Period ended 30 June 2026 Unaudited £'000	*Period ended 30 June 2025 Unaudited £'000*
IFRS 16 lease liability charge	**28**	*7*
Loan interest	**9**	-
Effective interest on convertible loan notes	**409**	*342*
Convertible loan note fees	**21**	*21*
	467	*370*

8. Income tax

	Period ended 30 June 2026 Unaudited £'000	*Period ended 30 June 2025 Unaudited £'000*
Current income tax charge	**-**	*(48)*

No income tax charge has been recognised in H1 26 due to the Group's significant carried forward tax losses. In addition, no R&D tax credit has been recognised during the period as no claim relating to the 2025 financial year has been submitted. The prior year tax movement arose from an adjustment following the overestimation of the 2024 R&D tax claim.

9. Earnings per share

Basic EPS is calculated by dividing the profit for the period attributable to ordinary equity holders of the parent by the weighted average number of equity shares outstanding during the period.

Diluted EPS is calculated by dividing the profit for the period attributable to ordinary equity holders of the parent (after adjusting for potential inflows/outflows on all dilutive potential shares) by the weighted average number of equity shares outstanding during the period plus the weighted average number of equity shares that would be issued on conversion of all the dilutive potential equity shares into equity shares.

	Period ended 30 June 2026 Unaudited £'000	*Period ended 30 June 2025 Unaudited £'000*
Total profit for the period after tax	**605**	*471*
Weighted average number of equity shares- Basic EPS:		
Ordinary shares	**367,095,247**	366,672,247
Weighted average number of equity shares- Diluted EPS:		
Ordinary shares	**367,095,247**	366,672,247
Share options	**2,716,738**	-
Convertible loan note	**231,798,715**	231,798,715
	601,610,700	598,470,962

Profit per share

	P	*P*
Basic	**0.2**	0.1
Diluted	**0.2**	0.1

10. Property, plant and equipment

During the six months ended 30 June 2026, the Group acquired computer equipment and office furniture with a cost of £16,158 (30 June 2025: £10,589).

11. Intangible assets

During the six months ended 30 June 2026, the Group capitalised platform development costs of £1,186,394 (30 June 2025: £1,166,237) and acquired the trade and assets of a weight management business for £910,768 (30 June 2025: nil). In addition, the Group incurred £163,951 of software development and staff implementation costs associated with third-party software (30 June 2025: £3,240).

12. Investments

Movement in the Group's investments during the financial period was as follows:

	Unaudited £'000
Balance as at 31 December 2025	**140**
Fair value adjustment	-
Balance as at 30 June 2026	**140**

The investments relate to the shareholding in My Emergency Doctor Limited. No fair value adjustment was recognised in the period.

13. Trade and other receivables

The following balances are due to be realised within one year of the reporting date:

	As at 30 June 2026 Unaudited £'000	As at 31 December 2025 Audited £'000
Trade receivables	**1,812**	1,544
Other receivables	**391**	233
Prepayments	**806**	1,009
Contract assets	**139**	210
	3,148	2,996

14. Trade and other payables: Amounts falling due within one year

	As at 30 June 2026 Unaudited £'000	As at 31 December 2025 Audited £'000
IFRS 16 lease liability <1 year	**268**	230
Trade payables	**1,568**	761
Other taxation and social security	**554**	515
Other payables	**123**	169
Accruals	**2,395**	3,302
Contract liabilities	**1,946**	768
	6,854	5,745

15. Trade and other payables: Amounts falling due after one year

	As at 30 June 2026 Unaudited £'000	As at 31 December 2025 Audited £'000
IFRS 16 lease liability >1 year	**354**	488
Other payables	**750**	750
	1,104	1,238

16. Loans and borrowings

	As at 30 June 2026 Unaudited £'000	*As at 31 December 2025 Audited £'000*
Current liabilities		
Amounts falling due within one year	**139**	*417*
Non-current liabilities		
Amounts falling due after one year	**9,220**	*8,790*

On 11 January 2024 the Company issued £10.6m of convertible loan notes. The key terms of the note are as follows:

- Convertible Notes are interest free and due 31 December 2027, with no repayment of principal required until maturity
- Conversion price of £0.04591 (A$0.0875), a premium of 94% to the closing price on 11 December 2023, the last trading date of the CDIs prior to the announcement of the transactions
- A Noteholder has the right to convert all or some of their notes upon issuance of conversion notice
- Initial £10.6m loan note split £7.7m to liability, £3.1m to equity with remaining £0.2m of transaction costs being unwound over the term of the notes
- Fair value of the liability was determined using an unsecured market rate of interest of 9.15% and discounted over the term of the loan
- Effective interest of £408,849 using the unsecured market rate of interest of 9.15%
- Zero coupon and no interim repayments
- Funds used to repay the AXA Loan and accrued interest of £0.4m
- AXA Health and Axia Investments Limited participated in the Convertible Notes

17. Financial instruments

As at 30 June 2026 the Group has the following financial assets and financial liabilities:

	As at 30 June 2026 Unaudited £'000	*As at 31 December 2025 Audited £'000*
Financial assets		
Current assets		
Held at amortised cost:		
Cash and cash equivalents	**7,676**	*6,575*
Other financial assets	**2,203**	*1,777*
	9,879	*8,352*
Financial liabilities		
Current liabilities		
Held at amortised cost:		
Loans and borrowings	**139**	*417*
Other financial liabilities	**4,354**	*4,462*
	4,493	*4,879*
Non-current liabilities		
Held at amortised cost:		
Loans and borrowings	**9,220**	*8,790*
Other financial liabilities	**1,104**	*1,238*
	10,324	*10,028*

Prepayments, contract assets and liabilities under the scope of IFRS 15, and tax and social security balances, are not considered financial instruments and are excluded from the table above.

Other current financial assets comprise trade and other debtors (see note 13), other current financial liabilities comprise IFRS 16 lease liabilities <1 year, trade payables, accruals, other payables (see note 14). Non-current other financial liabilities comprise other payables (see note 15) and loans and borrowings (see note 16).

18. Share options

The Group grants share options to certain of the Company's employees. The options have a range of vesting periods and exercise conditions.

The share-based payment charge included in the profit and loss account for the six months ended 30 June 2026 was £213,615 (30 June 2025: £102,015). Options granted during the period have been valued using the Black-Scholes model to determine the fair value at grant date.

	Weighted average exercise price (£)	**Number**	Weighted average exercise price (£)	Number
	Period ended 30 June 2026 Unaudited	**Period ended 30 June 2026 Unaudited**	Period ended 30 June 2025 Unaudited	Period ended 30 June 2025 Unaudited
Lapse of options in historic periods	**0.15**	**(12,009,938)**	-	-
Outstanding at beginning of the period	**0.09**	**74,206,747**	0.17	20,448,505
Granted during the period	**0.06**	**8,765,516**	0.07	51,999,975
Exercised during the period	**0.04**	**(423,000)**	-	-
Lapsed during the period	**0.06**	**(7,752,834)**	-	-
Outstanding at the end of the period	**0.07**	**62,786,491**	0.10	72,448,480
Exercisable at the end of the period	**0.07**	**26,274,725**	0.14	15,417,628

During the period, the Group performed a review of its outstanding share options and identified a number of historic share options that had lapsed in prior periods but had not previously been removed from the share option reserve. These lapsed options have now been reversed, with the associated balance transferred from the share option reserve to retained earnings through the Statement of Changes in Equity. The adjustment has no impact on the Group's profit or loss or net assets for the period.

The range of exercise prices in respect of options outstanding at 30 June 2026 is £0.00 to £0.30 (30 June 2025: £0.04 to £0.59). The weighted average remaining contractual life of outstanding options at 30 June 2026 is 5.5 years (30 June 2025: 5.6 years).

19. Related parties

For the six-month period ended 30 June 2026 & June 2025, the Directors considered themselves and the Chief Financial Officer as key management personnel. Key management personnel remuneration for the periods was as follows:

	Period ended 30 June 2026 Unaudited £'000	*Period ended 30 June 2025 Unaudited £'000*
Short-term employee benefits	**493**	*430*
Company contributions to defined contribution pension schemes	**1**	*2*
Share-based payment charge	**157**	*52*
	651	*484*

Amounts owed to the Group by Key Management Personnel at 30 June 2026 was £Nil (31 December 2025: £Nil).

All transactions with related parties were conducted on an arm's length basis under normal market terms and conditions.

20. Events after the reporting period

In July 2026 ASX granted the Company relief from the quarterly reporting requirements of Listing Rules 4.7B and 4.7C.

There were no other significant events occurring after the reporting period.

Directors’ Declaration

In the directors’ opinion:

a. The financial statements and notes set out on pages 13 to 23 are in accordance with the Corporations Act 2001, including:

> i) Complying with Accounting Standards, the Corporations Regulations 2001 and other mandatory professional reporting requirements; and
>
> ii) Giving a true and fair view of the consolidated entity’s financial position as at 30 June 2026 and of its performance for the half-year ended on that date; and

b. There are reasonable grounds to believe that Doctor Care Anywhere Group plc will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the directors.

John Stier

John Stier

Chair
Doctor Care Anywhere Group plc

Date: 17 August 2026

Independent Review Report to Doctor Care Anywhere Group plc

Conclusion

We have been engaged by Doctor Care Anywhere Group plc (the “Group”), to review the interim condensed set of financial statements in the half-yearly financial report for the six months ended 30 June 2026 which comprise the condensed consolidated statement of comprehensive income, condensed consolidated statement of financial position, condensed consolidated statement of changes in equity, condensed consolidated statement of cash flows and the related explanatory notes.

Based on our review, nothing has come to our attention that causes us to believe that the condensed set of financial statements in the half-yearly financial report for the six months ended 30 June 2026 is not prepared, in all material respects, in accordance with UK-adopted International Accounting Standard 34 ‘Interim Financial Reporting'.

Basis for conclusion

We conducted our review in accordance with International Standard on Review Engagements (UK) 2410 - “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued for use in the United Kingdom. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing (UK) and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

As disclosed in note 2, the annual financial statements of the Group are prepared in accordance with UK-adopted international accounting standards. The condensed set of financial statements included in this half-yearly report has been prepared in accordance with UK-adopted International Accounting Standard 34 “Interim Financial Reporting”.

Conclusions related to going concern

Based on our review procedures, which are less extensive than those performed in an audit as described in the Basis for Conclusion section of this report, nothing has come to our attention to suggest that management have inappropriately adopted the going concern basis of accounting or that management have identified material uncertainties relating to going concern that are not appropriately disclosed.

This conclusion is based on the review procedures performed in accordance with ISRE(UK) 2410, however future events or conditions may cause the entity to cease to continue as a going concern.

Responsibilities of directors

The directors are responsible for preparing the half-yearly financial report in accordance with UK adopted International Accounting Standard 34.

In preparing the half-yearly financial report, the directors are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.

Auditor's Responsibilities for the review of the financial information

Our responsibility is to express a conclusion to the company on the condensed set of financial statements in the half-yearly financial report based on our review.

Our conclusion, including our conclusions relating to going concern, are based on procedures that are less extensive than audit procedures, as described in the Basis for conclusion paragraph of this report.

Use of our report

This report is made solely to the Company in accordance with International Standard on Review Engagements (UK) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Financial Reporting Council. Our work has been undertaken so that we might state to the Company those matters we are required to state to it in an independent review report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company, for our review work, for this report, or for the conclusions we have formed.

Crowe U.K. LLP

Crowe U.K. LLP
Statutory Auditor, Chartered Accountants
London, UK
Date: 17 August 2026

Corporate Directory

Directors

John Stier	Independent Non-Executive Chairman
Laura O'Riordan	Chief Executive Officer
David Ravech	Non-Executive Director
Matthew Addison	Non-Executive Director
Samit Shah	Independent Non-Executive Director

Company Secretary

Computershare Company Secretarial Services Limited

Principal Registered Office in the UK

19-21 Great Portland Street, London, W1W 8QB

Share Register

Computershare Investor Services Pty Ltd, 452 Johnston Street, Abbotsford, VIC 3067

Tel: +61 3 9415 4000

Auditor

Crowe U.K. LLP, 55 Ludgate Hill, London, EC4M 7JW

Stock Exchange Listing

Doctor Care Anywhere Group plc shares are listed on the Australian Securities Exchange (Listing Code: DOC)

UK Company Number and ARBN

Company number: 08915336

ARBN: 645 163 873